复发的阿达曼蒂诺马图斯膜瘤显示MAPK通路激活,克隆进化和罕见的TP53损失介导的恶性进展
John R Apps1,2,3, Jose Mario Gonzalez-Meljem4,5, Romain Guiho4,6
1Institute of Cancer and Genomic Sciences, Edgbaston Campus, University of Birmingham, Birmingham, B15 2TT, UK. j.r.apps@bham.ac.uk.
Acta neuropathologica communications
|August 10, 2024
概括
复发性状瘤,特别是状瘤 (ACP),显示了克隆进化和MAPK/ERK通路激活. 还观察到TP53突变和免疫差异,这表明新的治疗点,如MAPK抑制剂.
科学领域:
- 神经瘤学神经瘤学
- 癌症生物学 癌症生物学
- 基因组学就是基因组学.
背景情况:
- 头骨瘤是一种罕见的脑瘤,主要有两种类型:形形 (ACP) 和乳头形 (PCP).
- 虽然人们越来越了解原发性瘤生物学,但驱动瘤复发的机制在很大程度上是未知的.
- 了解复发是改善患者治疗结果的关键.
研究的目的:
- 为了研究脑瘤复发背后的分子机制.
- 为了确定复发性喉瘤的潜在治疗点.
- 为了比较反复出现的ACP和PCP的生物特征.
主要方法:
- 使用甲基化阵列,RNA测序和pERK1/2免疫组织化学对联初级和复发性瘤样本的分析.
- 从一个大型脑瘤队列中分析全基因组测序数据.
- 用小鼠模型研究TP53突变的功能作用.
- 瘤免疫透的特征.
主要成果:
- 在反复出现的非洲和非洲国家病例中,观察到拷贝数量变化和克隆进化.
- 在复发性ACP中,MAPK/ERK通路激活是普遍存在的,除了具有CTNNB1突变和TP53损失的恶性病例.
- 在小鼠模型中,TP53的丧失导致了侵袭性瘤和降低生存率.
- 在ACP和PCP之间发现了不同的免疫细胞组成和空间分布.
结论:
- 复发性膜瘤表现出复杂的基因组变化和通路激活.
- TP53突变和特定的免疫特征与侵袭性疾病有关.
- MAPK通路抑制剂和免疫调节剂在治疗复发性ACP方面表现有前途.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
MAPK Signaling Cascades
5.3K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.3K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K


